1-3 of 3
David A. Westerman
Close
Sort by
Journal Articles

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors

Ella R. Thompson, Tamia Nguyen, Yamuna Kankanige, John F. Markham, Mary Ann Anderson, Sasanka M. Handunnetti, Rachel Thijssen, Paul Sung-Hao Yeh, Constantine S. Tam, John F. Seymour, Andrew W. Roberts, David A. Westerman, Piers Blombery
Journal: Blood Advances
Blood Adv (2022) 6 (2): 503–508.
https://doi.org/10.1182/bloodadvances.2021006211
Published: 2022
Includes: Supplemental data
Journal Articles

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

Clinical Trials & Observations
Thomas E. Lew, Victor S. Lin, Edward R. Cliff, Piers Blombery, Ella R. Thompson, Sasanka M. Handunnetti, David A. Westerman, Bryone J. Kuss, Constantine S. Tam, David C. S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson
Journal: Blood Advances
Blood Adv (2021) 5 (20): 4054–4058.
https://doi.org/10.1182/bloodadvances.2021005083
Published: 2021
Includes: Supplemental data
Journal Articles

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

Clinical Trials & Observations
Thomas E. Lew, Mary Ann Anderson, Victor S. Lin, Sasanka M. Handunnetti, Neil A. Came, Piers Blombery, David A. Westerman, Meaghan Wall, Constantine S. Tam, Andrew W. Roberts, John F. Seymour
Journal: Blood Advances
Blood Adv (2020) 4 (1): 165–173.
https://doi.org/10.1182/bloodadvances.2019000864
Published: 2020
Includes: Supplemental data